Mechanism of action in dogs of slow-acting insulin analog O346.
We compared metabolic effects as well as plasma and interstitial fluid kinetics of fatty acid-acylated insulin, Lys(B29)(N(epsilon)-omega-carboxynonadecanoyl)-des(B30) human insulin (O346), with previously determined kinetics of native insulin and insulin detemir. Euglycemic clamps with iv injection of O346 (90 pmol/kg) or saline control were performed in 10 male mongrel dogs under inhalant anesthesia. The t(1/2) for the clearance of O346 from plasma was 375.7 +/- 26.7 min; the t(1/2) for the appearance of O346 in interstitial fluid was 137 +/- 20 min (mean +/- SEM). Glucose disposal with O346 injection was increased 4-fold (t = 480 min, 8.3 +/- 1.42 mg/min/kg) compared with preinjection (t = 0 min, 2.1 +/- 0.13 mg/min/kg; P < 0.05) or saline control (t = 480 min, 2.09 +/- 0.22 mg/min/kg; P < 0.05). O346 plasma elimination and transendothelial transport were 0.3% and 3.5% of regular insulin and 3% and 50% of insulin detemir, respectively. Combination of in vivo results and compartmental modeling suggests that the duration of action of O346 after iv injection is about 25-fold and 10-fold longer compared with regular human insulin and insulin detemir, respectively. This study demonstrates that O346 stimulates glucose disposal very slowly, but when injected iv, its effect may be maintained for as long as 48 h as estimated from simulation analysis. The data suggest that O346 bound to albumin in plasma acts as a storage compartment for O346 from which the analog is slowly released to insulin-sensitive tissues. Reduced liver clearance of O346 is suggested to be the major mechanism for the protracted action.
Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
Martin
M
Ellmerer
Marianthe
M
Hamilton-Wessler
Stella P
SP
Kim
Melvin K
MK
Dea
Erlinda
E
Kirkman
Anjana
A
Perianayagam
Jan
J
Markussen
Richard N
RN
Bergman
D000818:Animals; D001783:Blood Flow Velocity; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D004285:Dogs; D005110:Extracellular Space / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005263:Femoral Artery; D005947:Glucose / Q000008:administration & dosage; D015309:Glucose Clamp Technique; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D008433:Mathematics; D008954:Models, Biological; D012709:Serum Albumin / Q000378:metabolism; D013552:Swine
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; C474229:Lys(B29)(N-carboxynonadecanoyl)-des(B30) human insulin; D012709:Serum Albumin; D005947:Glucose